Document is current
Any future updates will be listed below
-
Authors
Gerosa, Riccardo
Gelardi, Fabrizia
Tiberio, Paola
Jacobs, Flavia
Benvenuti, Chiara
Gaudio, Mariangela
Canzian, Jacopo
Tinterri, Benedetta
Zambelli, Alberto
Santoro, Armando
Antunovic, Lidija
De Sanctis, Rita https://orcid.org/0000-0003-3202-1933
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 16 October 2025
First Online: 1 December 2025
Declarations
:
: Declarations of interest: none related to the content of the manuscript or to the subject matter. Outside the submitted work, the authors declare the following financial interests/personal relationships: RG: Travel/meeting grants from Novartis and Daiichi Sankyo. AS: Advisory Board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp and Dohme (MSD). Consultancy: Arqule, Sanofi, Incyte. Speaker’s Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work). RDS: honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly, Gilead, and Ipsen (all outside the present work). AZ: honoraria and advisory board consultancy from Novartis, AstraZeneca, Lilly, Pfizer, Daiichi Sankyo, MSD, Roche, Seagen, Exact Sciences, Gilead, Istituto Gentili (all outside the present work).
: Not applicable.
: Not applicable.
: Not applicable.
